Cleared Special

EASYMAX Tag Self-Monitoring Blood Glucose System (K201258) - FDA 510(k) Clearance

Class II Chemistry device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K201258 · Eps Bio Technology Corp. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2021
Decision
478d
Days
Class 2
Risk

K201258 is an FDA 510(k) clearance for the EASYMAX Tag Self-Monitoring Blood Glucose System. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Eps Bio Technology Corp. (Hsinchu, TW). The FDA issued a Cleared decision on September 1, 2021 after a review of 478 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Eps Bio Technology Corp. devices

Submission Details

510(k) Number K201258 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 11, 2020
Decision Date September 01, 2021
Days to Decision 478 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
390d slower than avg
Panel avg: 88d · This submission: 478d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 165
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K201258.
MultiSure GK Link Blood Glucose and Ketone Monitoring System
K201880 · Apex BioTechnology Corp. · Oct 2021
CareSens N Feliz Blood Glucose Monitoring System, CareSens N Feliz BT Blood Glucose Monitoring System
K201394 · I-Sens, Inc. · Oct 2021
GlucoSure HT Plus Blood Glucose Monitoring System
K202885 · Apex BioTechnology Corp. · Sep 2021
CONTOUR® NEXT ONE Blood Glucose Monitoring System
K210687 · Ascensia Diabetes Care · Aug 2021
Finetest Lite Blood Glucose Monitoring System
K203562 · Osang Healthcare Co. , Ltd. · Jul 2021
Finetest Lite Smart Blood Glucose Monitoring System
K201396 · Osang Healthcare Co. , Ltd. · Oct 2020